Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

Autor: Niogret J; Department of Medical Oncology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France.; Department of Medical Oncology, University of Burgundy-Franche-Comté, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France.; INSERM U1231, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France.; Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France., Limagne E; Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France., Thibaudin M; Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France., Blanc J; Methodology, Data-Management, and Biostatistics Unit, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France., Bertaut A; Methodology, Data-Management, and Biostatistics Unit, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France., Le Malicot K; Department of Medical Oncology, University of Burgundy-Franche-Comté, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France.; Fédération Francophone de Cancérologie Digestive, EPICAD INSERM U1231, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France., Rinaldi Y; Department of Hepato-Gastroenterology, European Hospital, 6 Rue Désirée Clary, 13003 Marseille, France., Caroli-Bosc FX; Department of Gastroenterology, University Hospital Center, 4 Rue Larrey, 49100 Angers, France., Audemar F; Department of Gastroenterology, Côte Basque Hospital Center, 13 Avenue de l'Interne Jacques Loeb, 64100 Bayonne, France., Nguyen S; Department of Medical Oncology, Hospital Center, 4 Boulevard Hauterive, 64000 Pau, France., Sarda C; Department of Medical Oncology, Saintonge Hospital Center, 11 Boulevard Ambroise Paré, 17100 Saintes, France., Lombard-Bohas C; Department of Medical Oncology, Edouard Herriot Hospital, HCL, 5 Place d'Arsonval, 69003 Lyon, France., Locher C; Department of Gastroenterology, Est-Francilien Great Hospital, 6-8 Rue Saint-Fiacre, 77100 Meaux, France., Carreiro M; Department of Medical Oncology and Internal medicine, Hospital Center, 100 Rue Léon Cladel, 82000 Montauban, France., Legoux JL; Department of Hepato-Gastroenterology and Digestive Oncology, Regional Hospital Center, 14 Avenue de l'Hôpital, 45100 Orléans, France., Etienne PL; Department of Medical Oncology, CARIO, Côtes d'Armor Private Hospital, 10 Rue François Jacob, 22190 Plerin, France., Baconnier M; Department of Hepato-Gastroenterology, Annecy Genevois Hospital Center, 1 Avenue de l'Hôpital, 74374 Pringy, France., Porneuf M; Department of Medical Oncology and Hematology, Yves Le Foll Hospital Center, 10 Rue Marcel Proust, 22000 Saint-Brieuc, France., Aparicio T; Department of Gastroenterology, University Hospital Center Saint Louis, APHP, 1 Avenue Claude Vellefaux, 75010 Paris, France., Ghiringhelli F; Department of Medical Oncology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France.; Department of Medical Oncology, University of Burgundy-Franche-Comté, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France.; INSERM U1231, 7 Boulevard Jeanne d'Arc, 21000 Dijon, France.; Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 May 31; Vol. 12 (6). Date of Electronic Publication: 2020 May 31.
DOI: 10.3390/cancers12061429
Abstrakt: Background: Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan.
Methods: This study is a sub-study of PRODIGE-9 study, which included 488 mCRC patients treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab in first line. The association between splenic volume, and PFS and OS was evaluated by univariate and multivariable Cox analyses. The relation between circulating monocytic Myeloid derived suppressor cells (mMDSC) and splenomegaly was also determined.
Results: Baseline splenic volume > 180 mL was associated with poor PFS (median PFS = 9.2 versus 11.1 months; log-rank p = 0.0125), but was not statistically associated with OS (median OS = 22.6 versus 28.5 months; log-rank p = 0.1643). The increase in splenic volume at 3 months had no impact on PFS (HR 0.928; log-rank p = 0.56) or on OS (HR 0.843; log-rank p = 0.21). Baseline splenic volume was positively correlated with the level of baseline circulating mMDSC ( r = 0.48, p -value = 0.031).
Conclusion: Baseline splenomegaly is a prognostic biomarker in patients with mCRC treated with FOLFIRI and bevacizumab, and a surrogate marker of MDSC accumulation.
Databáze: MEDLINE
Externí odkaz: